Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
BMJ (Clinical Research Ed.)
|
June 22, 2011
Still waiting for functional EU Clinical Trials Register
Beate Wieseler, Natalie McGauran, Thomas Kaiser
Journal of the American Geriatrics Society
|
October 8, 2009
If shrimps had lips, they could whistle
Julia Kreis, Thomas Kaiser, Beate Wieseler
Journal of Clinical Epidemiology
|
April 8, 2026
When prices soar, progress stalls: How high drug costs hinder meaningful and ethical medical research
Philip Kranz, Natalie McGauran, Beate Wieseler
BMJ (Clinical Research Ed.)
|
July 12, 2019
New drugs: where did we go wrong and what can we do better?
Beate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)
|
November 28, 2012
We need access to data on all clinical trials, not just some
Beate Wieseler, Natalie McGauran, Thomas Kaiser
JAMA Internal Medicine
|
November 4, 2014
New EMA policy-further measures needed to support comparative effectiveness assessments
Beate Wieseler, Natalie McGauran, Thomas Kaiser
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
August 13, 2010
[False self-possession]
Monika Lelgemann, Beate Wieseler, Antes Gerd
The Lancet Regional Health. Europe
|
January 1, 2026
Generating evidence that meets the requirements of both regulatory agencies and HTA bodies
Beate Wieseler, Daniela Preukschat, Philip Kranz
Health Policy (Amsterdam, Netherlands)
|
December 3, 2014
Response to letter to the editor on "Early benefit assessment of new drugs in Germany--results from 2011 to 2012" [Health Policy 116(2-3) (2014) 147-153]
Helmut Hörn, Katrin Nink, Natalie McGauran, et al.
Deutsches Arzteblatt International
|
November 29, 2012
Early assessment of benefits
Thomas Kaiser, Stefan Lange, Beate Wieseler, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
BMJ (Clinical Research Ed.)
|
June 22, 2011
Still waiting for functional EU Clinical Trials Register
Beate Wieseler, Natalie McGauran, Thomas Kaiser
Journal of the American Geriatrics Society
|
October 8, 2009
If shrimps had lips, they could whistle
Julia Kreis, Thomas Kaiser, Beate Wieseler
Journal of Clinical Epidemiology
|
April 8, 2026
When prices soar, progress stalls: How high drug costs hinder meaningful and ethical medical research
Philip Kranz, Natalie McGauran, Beate Wieseler
BMJ (Clinical Research Ed.)
|
July 12, 2019
New drugs: where did we go wrong and what can we do better?
Beate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)
|
November 28, 2012
We need access to data on all clinical trials, not just some
Beate Wieseler, Natalie McGauran, Thomas Kaiser
JAMA Internal Medicine
|
November 4, 2014
New EMA policy-further measures needed to support comparative effectiveness assessments
Beate Wieseler, Natalie McGauran, Thomas Kaiser
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
August 13, 2010
[False self-possession]
Monika Lelgemann, Beate Wieseler, Antes Gerd
The Lancet Regional Health. Europe
|
January 1, 2026
Generating evidence that meets the requirements of both regulatory agencies and HTA bodies
Beate Wieseler, Daniela Preukschat, Philip Kranz
Health Policy (Amsterdam, Netherlands)
|
December 3, 2014
Response to letter to the editor on "Early benefit assessment of new drugs in Germany--results from 2011 to 2012" [Health Policy 116(2-3) (2014) 147-153]
Helmut Hörn, Katrin Nink, Natalie McGauran, et al.
Deutsches Arzteblatt International
|
November 29, 2012
Early assessment of benefits
Thomas Kaiser, Stefan Lange, Beate Wieseler, et al.
Page
of 5